The Company maintains a strong, strategic portfolio of intellectual property, patent applications and proprietary operating procedural processes that form its Adipose Tissue Processing Platform, which in turn, supports the growing pipeline of biologic products and processes, clinical services and international licensing opportunities. More specifically, this platform enables the cryopreservation of an individual’s adipose tissue which when needed can be further clinically processed into Stromal Vascular Fraction (SVF), which contains ADRCs, other regenerative cells, including white blood cells, endothelial cells, smooth muscle cells, pericytes, fibroblasts and pre-adipocytes, among others.
CRYO